'Abciximab' presentation slideshows

MANAGEMENT OF CARDIAC SURGICAL PATIENTS RECEIVING PLATELET INHIBITORS

MANAGEMENT OF CARDIAC SURGICAL PATIENTS RECEIVING PLATELET INHIBITORS. Jerrold H. Levy, MD Professor of Anesthesiology Emory University School of Medicine Director of Cardiothoracic Anesthesiology Emory Healthcare Atlanta, Georgia. Events Leading to Thrombus Formation. Adhesion.

477 views • 38 slides

Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary

343 views • 24 slides

Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA

Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI trial. Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA. Disclosure. Atrium Medical: Consultant, Research support, Training and speaking Honorarium Eli Lilly: Speaker Honorariums.

368 views • 19 slides

Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary

Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention The Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI ) trial. Holger Thiele, MD;

280 views • 18 slides

Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary

Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention The Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI ) trial. Holger Thiele, MD;

364 views • 18 slides

BCIS Annual Meeting London January 2006

BCIS Annual Meeting London January 2006. Primary Angioplasty for Acute MI Who are the Stakeholders?. Dr Bernard Prendergast DM FRCP Wythenshawe Hospital Manchester UK. NO CONFLICT OF INTEREST TO DECLARE. Manchester Cardiac Services 2001. PCI projections Greater Manchester 2005-6.

301 views • 16 slides

Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics

ISAR-SWEET Trial. Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics . Presented at American Heart Association Scientific Sessions 2004 Presented by Dr. Julinda Mehilli . ISAR-SWEET Trial.

167 views • 6 slides

FINESSE: Study Design

FINESSE: Study Design. Acute ST Elevation MI (or New LBBB) within 6h pain onset Presenting at Hub or Spoke with estimated time to Cath between 1 and 4 hours. Randomize 1:1:1 N=3000. Double Blind Double Dummy. *Only 5U if ? 75yr. Placebo Placebo.

266 views • 4 slides

Results

FINESSE.

106 views • 1 slides